Common use of Publications and Presentations Clause in Contracts

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) that relate to the Research Program [********] at least [********] prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. Further, AstraZeneca shall [********]. Once an abstract, manuscript or presentation has been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a Party [********], the same abstract, manuscript or presentation does not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except Except as required by Applicable Laws, each Party agrees that it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the other Party JSC the opportunity to review each any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) that which relate to the Research Program [********] Program, the Development of a Candidate or the Commercialization of a Product at least [********] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given TSC within such [********] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it which the JSC reasonably believes may be is patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in by the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a Party [********]JSC, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party JSC for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program or any Development Program without the prior review by and approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] or any Development Program at least [********] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, and approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. All such abstractsEach Party (i) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, manuscripts presentation at scientific conferences and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith meetings and (bii) permit AstraZeneca agrees that it shall not unreasonably withhold, condition or delay its consent to review and comment on any such publicationrequest by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program without the prior review by and approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] at least [********] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] ]day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed andand approved by each Party, the subject matter disclosed in such abstracts, manuscripts Portions of this Exhibit were omitted and have been filed separately with the case Secretary of any abstract, manuscript or presentation that relates the Commission pursuant to the Research Program, approved by a Party [********], Company's application requesting confidential treatment under Rule 406 of the same abstract, manuscript Securities Act. 41 or presentation presentations does not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. All such abstractsSubject to the foregoing obligations of this Section 6.3, manuscripts TAKEDA may use the results of the Research Program for the purpose and to the extent necessary to develop and commercialise Products in accordance with this Agreement. Notwithstanding the foregoing, TAKEDA shall exclusively control all scientific publications and presentations that contain any data relating to an Optimized Lead Compound or Product. ARCHEMIX agrees that, except as required by Applicable Laws, it shall not publish or on behalf present, or permit to be published or presented, any data arising out of Targacept shall [********]. Notwithstanding anything in this Section 7.3 the Development Program relating to an Optimized Lead Compound or Product without the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to prior review and comment on any such publicationexpress written approval of TAKEDA which may be withheld at TAKEDA’s sole discretion.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program or any Development Program without the prior review by and approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] or any Development Program at least [********] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, and approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. All such abstractsEach Party (i) expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, manuscripts presentation at scientific conferences and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith meetings and (bii) permit AstraZeneca agrees that it shall not unreasonably withhold, condition or delay its consent to review and comment on any such publicationrequest by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the research conducted by sanofi-aventis under or pursuant to this Agreement to the extent such results refer to or otherwise relate to the Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] Covered Results at least [***] ([*****] ]) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [*****]-[***] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([*****] ]) days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, and approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that BioNTech shall have the sole right, either itself or through its Affiliates or Sublicensees, to present or publish the results of, or scientific publications and presentations must be strictly monitored information relating to, any activities under this Agreement PROVIDED THAT prior to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [***] the Parties will agree through the JSC on the content of any publications relating to the [***] and/or [***]. Each Biotheus shall not make any publication or presentation relating to a Licensed Compound or Licensed Product without the prior written consent of BioNTech. If, in accordance with the requirements and limitations of this Section 10.3 (Publications and Presentations), a Party shall provide desires to publicly present or publish results or scientific information relating to a Licensed Compound or Licensed Product which publication contains the other Party the opportunity to review each Confidential Information of the submitting non-publishing Party’s , prior to doing so, the publishing Party will provide non-publishing Party with drafts of proposed abstracts, manuscripts or summaries of presentations (including information to be presented verbally) that relate to the Research Program include such results or information. The non-publishing Party will respond no later than [********] at least [********] prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] from the date days after receipt of such written request to seek appropriate patent protection for any material in such proposed publication or presentation that it reasonably believes or such shorter period as may be patentableagreed to by the Parties. Further, AstraZeneca shall [********]. Once an abstract, manuscript or presentation has been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a The publishing Party [********], the same abstract, manuscript or presentation does not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in will delay any such proposed publication or presentation be deleted prior for a period up [***] days after the non-publishing Party receives such proposed publication or presentation to permit the non-publishing Party to make filings for patent protection and will otherwise remove its Confidential Information identified by the non-publishing Party in such publication or presentation. In any permitted publication or presentation by a Party, The Parties agree to acknowledge the other Party’s contribution shall be duly recognized, and co-authorship shall be determined contributions of one another in accordance with customary standardsstandard academic practice regarding authorship of scientific publication. All Each Party agrees to comply, with respect to the listing of Clinical Trials or the publication of Clinical Trial information and results with respect to Licensed Products and to the extent applicable to its activities conducted under this Agreement, with any Applicable Law or applicable court order, stipulations, consent agreements and settlements entered into by such abstracts, manuscripts Party; provided that any listings or publications made pursuant to this Section 10.3 (Publications and presentations by or on behalf of Targacept shall Presentations). [***] will provide such assistance as [***] may reasonably require to obtain any consent or permission that may be required in order to publish data that originates from [***]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except Except as required by Applicable Laws, each Party agrees that it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the other Party JSC the opportunity to review each any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) that which relate to the Research Program [********] Program, the Development of a Candidate or the Commercialization of a Product at least [********] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given TSC within such [********] day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it which the JSC reasonably believes may be is patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in by the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a Party [********]JSC, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party JSC for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission. contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except Except as required by Applicable Laws, each Party agrees that it shall [********]not publish or present, or permit to be published or presented, the results of the Development Program or the Development or Commercialization of a Collaboration Product or Collaboration Service, including but not limited to, studies or clinical trials carried out by such Party as part of the Collaboration under this Agreement, without the prior review by and the approval of the other Party. Each Party shall provide to the other Party the opportunity to review each any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) that which relate to the Research Development Program [********] or the Development or the Commercialization of a Collaboration Product or Collaboration Service at least [********] thirty (30) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] thirty (30) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] sixty (60) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it which the other Party reasonably believes may be is patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in by the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a Party [********]other Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again again, to the other either Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, recognized and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts Portions of this Exhibit were omitted and presentations by or on behalf have been filed separately with the Secretary of Targacept shall [********]. Notwithstanding anything in this Section 7.3 the Commission pursuant to the contrary, Targacept shall [********] publication in connection with Company’s application requesting confidential treatment under Rule 406 of the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publicationSecurities Act.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except Except as required by Applicable Laws, each Party agrees that it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program, the Development of a Candidate or the Commercialization of a Product, including, but not limited to, studies or clinical trials carried out by such Party as part of Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission. the Collaboration, without the prior review by and the approval of the JSC in accordance with Section 2.1. Each Party shall provide to the other Party JSC the opportunity to review each any of the submitting Party’s proposed abstracts, manuscripts or presentations (including information to be presented verbally) that which relate to the Research Program [********] Program, the Development of a Candidate or the Commercialization of a Product at least [********] prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given TSC within such [********] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it which the JSC reasonably believes may be is patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in by the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a Party [********]JSC, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party JSC for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Notwithstanding anything to the contrary contained herein, the right to publish or present, or permit to be published or presented, the results of the Research Program shall be governed by the terms of the Collaborative Research Agreement. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Development Program without the prior review by the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Development Program [********] at least [* (********] ) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [* (********] ) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [* (********] ) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. FurtherIn the event that the Parties disagree on a proposed publication or presentation, AstraZeneca they will discuss the matter in good faith and ARQULE shall [********]have the right to make the final decision on publication or presentation of the results of the Research Program and DS shall have the right to make the final decision on publication or presentation of the results of the Development Program. Once an abstractsuch abstracts, manuscript manuscripts or presentation has presentations have been reviewed and, published or presented by each Party in the case of any abstract, manuscript or presentation that relates to the Research Program, approved by a Party [********]accordance with this Section 5.3, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation, provided that ARQULE shall be permitted to use data generated by ARQULE and information about AKT in any such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. All such abstractsEach Party expressly acknowledges that the other Party’s business may be substantially dependent on its ability to publish results in scientific journals, manuscripts presentation at scientific conferences and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publicationmeetings.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program or the Development or Commercialization of a Licensed Product to the extent such results refer to or otherwise relate to the Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] Covered Results at least [********] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period], not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, and approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Development or Commercialization of a Licensed Product to the extent such results refer to or otherwise relate to the Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] Covered Results at least [***] ([*****] ]) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [*****]-[***] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([*****] ]) days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, and approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program or the Development Program without the prior review by and written approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] or the Development Program at least [* (********] ) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [* (********] ) day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [* (********] ) days from the date of such written request to seek appropriate patent protection for any material in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, and approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall Each Party (a) coordinate expressly acknowledges that the other Party’s business may be substantially dependent on its activities ability to publish results in connection therewith with AstraZeneca in good faith scientific journals, presentation at scientific conferences and meetings and (b) permit AstraZeneca agrees that it shall not unreasonably withhold, condition or delay its consent to review and comment on any such publicationrequest by the other Party to publish results of the Research Program or any Development Program in accordance with its internal publication guidelines.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Research Program or the Development or Commercialization of a Licensed Product to the extent such results refer to or otherwise relate to the Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] Covered Results at least [********] days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period], not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [********] days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, and approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognizedPortions of this Exhibit, and co-authorship shall be determined in accordance with customary standards. All such abstracts, manuscripts and presentations indicated by or on behalf of Targacept shall the xxxx “[********]. Notwithstanding anything in this Section 7.3 ,” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the contraryRegistrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publicationas amended.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party ImmunoGen agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Development and Commercialization of a Licensed Product to the extent such results refer to, derive from or otherwise relate to the Licensed Intellectual Property without the prior review by and approval of Novartis. Each Party Novartis shall provide to the other Party ImmunoGen the opportunity to review each of the submitting Party’s Novartis’ proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] contain ImmunoGen’s Confidential Information or disclose any unpatented Licensed Technology at least [********] days prior to its intended presentation or submission for publication, and such submitting Party Novartis agrees, upon written request from the other Party ImmunoGen given within such [********] ]-day period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party ImmunoGen is given up to [********] days from the date of such written request to seek appropriate patent protection for any material unpatented Licensed Technology disclosed in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Programwhere applicable, approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for or publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.

Publications and Presentations. The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Each Party agrees that, except as required by Applicable Laws, it shall [********]not publish or present, or permit to be published or presented, the results of the Development or Commercialization of a Licensed Product to the extent such results refer to or otherwise relate to the Licensed Technology or Licensed Patent Rights (the “Covered Results”) without the prior review by and approval of the other Party. Each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or presentations (including including, without limitation, information to be presented verbally) that relate to the Research Program [********] Covered Results at least [***] ([*****] ]) days prior to its intended presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [********] period, not to submit such abstract or manuscript for publication or to make such presentation until the other Party is given up to [***] ([*****] ]) days from the date of such written request to seek appropriate patent protection for any material Covered Rights in such publication or presentation that it reasonably believes may be patentable. FurtherOnce such abstracts, AstraZeneca shall [********]. Once an abstract, manuscript manuscripts or presentation has presentations have been reviewed and, in the case of any abstract, manuscript or presentation that relates to the Research Program, and approved by a Party [********]each Party, the same abstractabstracts, manuscript manuscripts or presentation does presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or presentation be deleted prior to such publication or presentation. In any permitted publication or presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary industry standards. All such abstracts, manuscripts and presentations by or on behalf of Targacept shall [********]. Notwithstanding anything in this Section 7.3 to the contrary, Targacept shall [********] publication in connection with the Ongoing Ispronicline Trial; provided that Targacept shall (a) coordinate its activities in connection therewith with AstraZeneca in good faith and (b) permit AstraZeneca to review and comment on any such publication.